Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Post by farmerjaneon Feb 06, 2012 11:51am
209 Views
Post# 19494868

Is Amorfix with holding relevant information

Is Amorfix with holding relevant information

Retired Cop in reference to some of your comments:

  • James is gone, Dr.Gundel was the CEO and very much involved in those projections.
  • My point was that in Jan/11 they presented in San Fran financial stability, then in Feb, issued themselves .5M in common shares ,which I believe caught everyone off guard, and the different placements since then for different amounts not lining up at all.
  • The A4 test, Dr. Gundel said in Nov/11 they haven't marketed the product, do not recalla any NR 's about sales person on commission. Concerning the patent I am referring to a blog you posted on Dec14/11, the footnotes of the article published the patent being submitted by an employee HW(Hong Wan) of Pfizer BioTherapeutics and LS (Louse Scrocchi) an employee of Amorfix This article was received by the Medical Journal on June 24/11, accepted on Oct 9/11 and published on Nov 11/11. This was the basis of my comments around the A4 test, why was this patent filed by the employees of these companies and not the companies themselves. 
  • I am not convinced that other financial firms hold large amounts of stock in this company. Interinvest and Cashman hold approximately 25% alone and if you knew what the old Amorfix guard has and a few others it's probally a tightly held stock. If other investment companies were buying at the pace Interinvest is each month you would see a different stock price.
  • Lastly refreshing the Amorfix web page does not do any thing for keeping the Web site updated. 
Bullboard Posts